{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Answers from the Lab","title":"TPNUQ: Ann Moyer, M.D., Ph.D.","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/f533b362\"></iframe>","width":"100%","height":180,"duration":811,"description":"Ann Moyer, M.D., Ph.D., explains Mayo Clinic Laboratories' genotype evaluation for thiopurine metabolization. This test, TPNUQ, evaluates two genes – TPMT and NUDT15 – for variations strongly associated with thiopurine-related toxicity. Performed prior to therapy initiation, TPNUQ examines more alleles than other clinically available genotype tests, enabling clarity for more patients whose ethnic backgrounds might put them at greater risk for medication-related toxicity. ","thumbnail_url":"https://img.transistorcdn.com/jhRCftFebxnTMwoIbA_WoqrSKwFRD_Y2kbh0JDjhx14/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lYjNj/ZDc0NTE0MWNlOWRl/YzRiN2Q3NDg2Mjg5/YWE4MS5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}